Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera

Status: Withdrawn

Conditions: Carcinoma of the Skin; AML; Carcinoma, Renal Cell; Carcinoma Bladder; Cholangiocarcinoma; Carcinoma of the Appendix; Carcinoma of the Oral Cavity; Carcinoma Prostate; Carcinoma of the Paranasal Sinus; Carcinoma of the Lip; Multiple Myeloma in Relapse; Carcinoma, Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma, Neuroendocrine; Carcinoma Cervix; Carcinoma of Esophagus; Carcinoma of the Penis; Carcinoma, Ductal; Carcinoma of the Oropharynx; Carcinoma of the Larynx; Carcinoma, Hepatocellular; Carcinoma, Pancreatic; Carcinoma of the Head and Neck; Carcinoma; Malignant Pleural Effusion; Carcinoma of Lung; Carcinoma, Thymic; Stage III Lung Cancer; Carcinoma of Unknown Primary; Carcinoma Breast; Carcinoma, Ovarian; Carcinoma of the Anus; Stage III Breast Cancer; Mesothelioma; Malignant Ascites; Carcinoma of the Vulva; Stage IV Lung Cancer; Stage IV Breast Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04985357

TRV-002

Details and patient eligibility

About

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Sample collection or biopsy of tumor is clinically indicated as part of SOC
• Prior to preceding onto therapy for treatment

Exclusion criteria

• Unable to obtain sufficient sample

Trial design

0 participants in 6 patient groups

Carcinoma-Associated Malignant Fluid

Description:

Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Carcinoma Solid Tissue Specimen

Description:

Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Multiple Myeloma

Description:

Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Acute myelogenous leukemia (AML)

Description:

Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Triple Negative Breast Cancer (TNBC)

Description:

Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Peripheral Blood Cell Immune Competency

Description:

Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.